RACE ONCOLOGY LTD

4.02%

$1.20

Market Cap $207.6M

Healthcare Biotechnology

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a... Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.More

Corporate Spotlight

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.
View the full Corporate Spotlight

RAC Accelerates Game-Changing Cancer Drug

Latest Threads

Tag

Subject

RAC Biotech

RAC - Charts & Price Action

442 443 444

14:49

26K

10M

14:49

Last post johndprent

26K

10M

RAC

megan baldwin

14:16

5.4K

14:16

Last post jm69

5.4K

RAC

General Comments / Chat

232 233 234

19/08/25

14K

5.2M

19/08/25

Last post DDD24

14K

5.2M

RAC

Industry news

52 53 54

19/08/25

3.2K

1.1M

19/08/25

Last post ma420

3.2K

1.1M

RAC

$1.25 piggyback options

16/08/25

10K

16/08/25

Last post Hunterr

10K

RAC

Cardioprotection thread

19 20 21

11/08/25

1.2K

418K

11/08/25

Last post Rhino1963

1.2K

418K

RAC

Ann: RC220 Human Ethics Approvals Received in Hong Kong

11/08/25

13K

11/08/25

Last post nextdl

13K

RAC

Chat GPT Q&A

6 7 8

11/08/25

475

184K

11/08/25

Last post Hunterr

475

184K

RAC

I'm keen to understand

10/08/25

101

30K

10/08/25

Last post asx11

101

30K

RAC

Ann: Phase 2 Bisantrene AML Trial Results Published

09/08/25

21K

09/08/25

Last post couldwellb

21K

RAC

hailey baldwin

08/08/25

669

08/08/25

Last post Roger233

669

RAC

RAC media coverage

45 46 47

08/08/25

2.8K

995K

08/08/25

Last post Roger233

2.8K

995K

RAC

Ann: Race Oncology Upcoming 2025 Investor Events

07/08/25

18K

07/08/25

Last post optic

18K

RAC

Who has been selling and why?

06/08/25

2.2K

06/08/25

Last post stewar1t

2.2K

RAC

Ann: First Patient Dosed Safely in RC220 Phase 1 Trial

2 3 4

01/08/25

202

75K

01/08/25

Last post bellmatic

202

75K

RAC Biotech

Nanobots in Oncology

31/07/25

2.7K

31/07/25

Last post The Knightrider

2.7K

See All Discussions

Corporate Spotlight

ABOUT US

Timeline

Phase 2 Bisantrene AML Trial Results Published
04 Aug 13:57	Share

Notification regarding unquoted securities - RAC
24 Jul 16:34	Share

June 2025 Quarterly Activity Report and Appendix 4C
23 Jul 08:28	Share

Race Oncology Upcoming 2025 Investor Events
15 Jul 13:29	Share

RC220 Human Ethics Approvals Received in Hong Kong
10 Jul 09:07	Share

Application for quotation of securities - RAC
26 Jun 13:49	Share

Application for quotation of securities - RAC
19 Jun 14:35	Share

First Patient Safely Combine Dosed in Phase 1 RC220 Trial
19 Jun 08:56	Share

Termination of City of Hope Global IP License
17 Jun 08:57	Share

Application for quotation of securities - RAC
06 Jun 11:54	Share

Notification of cessation of securities - RAC
03 Jun 10:27	Share

Race Gold Coast Brisbane Investor Events
02 Jun 12:14	Share

Application for quotation of securities - RAC
29 May 16:11	Share

Application for quotation of securities - RAC
22 May 11:14	Share

Application for quotation of securities - RAC
07 May 11:09	Share

Notification of cessation of securities - RAC
06 May 15:51	Share

Race Announces Key Senior Clinical Team Appointments
05 May 08:57	Share

First Patient Dosed Safely in RC220 Phase 1 Trial
01 May 08:57	Share

March 2025 Quarterly Activity Report and Appendix 4C
23 Apr 08:41	Share

Enrolment Opened at Second Site for RC220 Phase 1 Trial
22 Apr 08:56	Share

RC220 Phase 1 Trial Opens for Patient Enrolment
03 Apr 08:57	Share

Ethics approval for RC220 Trial at Gosford Wyong Hospitals
31 Mar 17:41	Share

Race Initiates First AU Site for Phase 1 Solid Tumour Trial
27 Mar 15:53	Share

Race Investor Presentation
17 Mar 16:53	Share

Race Online Investor Briefing Invitation
14 Mar 11:08	Share

Ethics approval received for RC220 Phase 1 Trial
14 Mar 08:47	Share

S&P DJI Announces March 2025 Quarterly Rebalance
07 Mar 17:01	Share

Race Signs Contract for Phase 1 Trial of RC220
05 Mar 08:58	Share

Appendix 4D & Half-Year Financial Statements
25 Feb 13:42	Share

Application for quotation of securities - RAC
04 Feb 13:06	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.20		Change -0.050(4.02%)		Mkt cap ! $207.6M

Open	High	Low	Value	Volume
$1.24	$1.24	$1.18	$86.25K	72.38K

Buyers (Bids)

No.	Vol.	Price($)
1	792	$1.19

Sellers (Offers)

Price($)	Vol.	No.
$1.21	5693	2

View Market Depth

No.	Vol.	Price($)
1	792	1.190
1	1544	1.185
1	5495	1.180
4	17137	1.170
2	7103	1.165

Price($)	Vol.	No.
1.210	118	1
1.220	5693	2
1.225	1900	1
1.230	1000	1
1.245	22517	3

Last trade - 14.40pm 20/08/2025 (20 minute delay)


Last $1.20		Change -0.050 ( 0.84 %)
Open	High	Low	Volume
$1.19	$1.22	$1.18	5231
Last updated 15.13pm 20/08/2025 ?

RAC (ASX) Chart

RACE ONCOLOGY LTD

Corporate Spotlight

Latest Threads

Redcastle Resources (ASX:RC1): Strategic JV to Expedite Gold Production & Major Tenement Expansion in Eastern Goldfields

Corporate Spotlight

Timeline

Featured News

Latest Videos

Race Oncology accelerates gamechanging cancer drug

02 Jul 2025 09:48 (AEST)

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

14 May 2024 09:56 (AEST)

Race Oncology (ASX:RAC) strikes contracts to start observational breast cancer trial

13 Mar 2023 15:00 (AEDT)

Latest Articles

Race Oncology approved for Phase I trial for chemotherapeutic treatments

Race Oncology Ltd has received approval to go ahead with its Phase I trial to assess R220 and begin enrolling patients

Race identifies 39 new molecules with potential to inhibit cancer-associated protein

Race Oncology Ltd has completed a successful drug discovery program started in 2022 at Monash University in Melbourne

Race delivers promising results in cancer drug mice research into heart complications

Race Oncology (ASX:RAC) has announced a preclinical breakthrough in heart toxicity side effects caused by the carfilzomib, which had precluded the drug being administered to patients diagnosed with elevated cardiac risk factors.In work performed under contract by Labcorp in the United States, Rac...

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News